CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 249 enrolled
Drug / intervention
C-peptide concentrationsother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04005261
NCT04005261N/ACompleted
CompareCT.gov

Is it Time to Revise Type 2 Diabetes Treatment: C-peptide Concentrations in Type 2 Diabetes Treated With Insulin

Goztepe Training and Research Hospital·observational·Posted Jul 2, 2019·Updated Jul 2, 2019

In Brief

An observational study evaluating C-peptide concentrations for Type 2 Diabetes Treated With Insulin. Completed, enrolled 249 participants across 1 site.

Detailed Summary

C-peptide is used to evaluate beta cell reserves. Patients with type 2 diabetes are treated with insulin for different indications. Other than beta-cell insufficiency and organ failures, insulin treatment is needed for a specified period. The investigators want to evaluate beta cell reserves in patients with type 2 diabetes treated with insulin for at least six months to see if that is the case. The investigators also want to compare the characteristics of these patients according to their beta cell reserves.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Treated With Insulin
CountriesTurkey (Türkiye)
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedJul 2, 2019
Enrollment StartNov 1, 2018
Primary CompletionFeb 1, 2019
Study CompletionMar 1, 2019
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 7 years ago

Interventions

C-peptide concentrationsother

The patients will be grouped by their C-peptide concentrations